` GLUE (Monte Rosa Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

GLUE
vs
S&P 500

Over the past 12 months, GLUE has underperformed S&P 500, delivering a return of -20% compared to the S&P 500's 12% growth.

Stocks Performance
GLUE vs S&P 500

Loading
GLUE
S&P 500
Add Stock

Performance Gap
GLUE vs S&P 500

Loading
GLUE
S&P 500
Difference

Performance By Year
GLUE vs S&P 500

Loading
GLUE
S&P 500
Add Stock

Competitors Performance
Monte Rosa Therapeutics Inc vs Peers

S&P 500
GLUE
ABBV
AMGN
GILD
VRTX
Add Stock

Monte Rosa Therapeutics Inc
Glance View

Market Cap
244.8m USD
Industry
Biotechnology

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-06-24. The company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops a protein degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN), that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. The company focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. Its lead product candidate is MRT-2359, which is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways.

GLUE Intrinsic Value
7.6 USD
Undervaluation 48%
Intrinsic Value
Price
M
Back to Top